Literature DB >> 23073789

A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.

Randy L Carter1, Le Kang, Kathleen M Darcy, James Kauderer, Shu-Yuan Liao, William H Rodgers, Joan L Walker, Heather A Lankes, S Terence Dunn, Eric J Stanbridge.   

Abstract

PURPOSE: In the absence of gold standard diagnoses, we estimate age-specific false-positive and false-negative prediction rates of HPV-, cytology-, and histology-based tests for significant cervical lesions (SCL) in US women with AGC-NOS Pap smear diagnoses.
METHODS: Modified Latent Class Model (LCM) analyses, with prevalence of SCL modeled as a function of age, were applied to GOG-0171 study data (n = 122). The accuracies of several HPV-based tests, including Hybrid Capture II high-risk HPV (HC2 H-HPV); carbonic anhydrase IX (CA-IX); and invasive histological diagnosis, were compared. 1-PPV and 1-NPV were written as functions of sensitivity, specificity, and prevalence to obtain age-specific false-positive and false-negative rates.
RESULTS: The histology-based test was nearly perfect (sensitivity = 1.00, CI = 0.98-1.00; specificity = 0.99, CI = 0.96-1.00). Otherwise, HC2 H-HPV performed best (sensitivity = 1.00, CI = 1.00-1.00; specificity = 0.87, CI = 0.79-0.94). The false-positive detection rates (1-PPV) for HC2 H-HPV were high (>17 %) at each age, while those of the histological diagnoses were low (<5 % at ages ≤60 and <17 % overall ages). False-negative prediction rates (1-NPV) for HC2 H-HPV were <0.11 % at each age and were uniformly lower than those of other tests, including the histology-based test (<0.25 %). CA-IX together with HC2 H-HPV did not improve performance.
CONCLUSIONS: Women with negative HC2 H-HPV can safely forego invasive treatment (i.e., cone or LEEP biopsy, hysterectomy) in favor of observational follow-up. Additional biomarkers must be found for use in combination with HC2 H-HPV to reduce false-positive rates. This novel application of a modified LCM exemplifies methods for potential use in future cancer screening studies when gold standard diagnoses are not available.

Entities:  

Mesh:

Year:  2012        PMID: 23073789      PMCID: PMC3499682          DOI: 10.1007/s10552-012-0081-0

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  26 in total

1.  Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail.

Authors:  Mario Poljak; Irena J Marin; Katja Seme; Adriana Vince
Journal:  J Clin Virol       Date:  2002-12       Impact factor: 3.168

2.  Inappropriate gold standard bias in cervical cancer screening studies.

Authors:  Robert G Pretorius; Yan-Ping Bao; Jerome L Belinson; Raoul J Burchette; Jennifer S Smith; You-Lin Qiao
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

Review 3.  Evaluating diagnostic tests with imperfect standards.

Authors:  P N Valenstein
Journal:  Am J Clin Pathol       Date:  1990-02       Impact factor: 2.493

4.  Latent class analysis of diagnostic agreement.

Authors:  J S Uebersax; W M Grove
Journal:  Stat Med       Date:  1990-05       Impact factor: 2.373

Review 5.  Estimation of test error rates, disease prevalence and relative risk from misclassified data: a review.

Authors:  S D Walter; L M Irwig
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

6.  Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis.

Authors:  E R Myers; D C McCrory; K Nanda; L Bastian; D B Matchar
Journal:  Am J Epidemiol       Date:  2000-06-15       Impact factor: 4.897

7.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

Review 8.  Human papillomavirus and cervical cancer.

Authors:  Mark Schiffman; Philip E Castle; Jose Jeronimo; Ana C Rodriguez; Sholom Wacholder
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

9.  A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study.

Authors:  Patti E Gravitt; Mark Schiffman; Diane Solomon; Cosette M Wheeler; Philip E Castle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

10.  Visual inspection with acetic acid as a cervical cancer test: accuracy validated using latent class analysis.

Authors:  Lynne Gaffikin; John A McGrath; Marc Arbyn; Paul D Blumenthal
Journal:  BMC Med Res Methodol       Date:  2007-07-31       Impact factor: 4.615

View more
  1 in total

1.  Triage of Atypical Glandular Cell by SOX1 and POU4F3 Methylation: A Taiwanese Gynecologic Oncology Group (TGOG) Study.

Authors:  Cheng-Chang Chang; Yu-Che Ou; Kung-Liahng Wang; Ting-Chang Chang; Ya-Min Cheng; Chi-Hau Chen; Tang-Yuan Chu; Shih-Tien Hsu; Wen-Shiung Liou; Yin-Yi Chang; Hua-Hsi Wu; Tze-Ho Chen; Hung-Cheng Lai
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.